Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by HENDERSON, R.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 Oxford University Press

research-article

The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery*

REBECCA HENDERSON

Massachusetts Institute of Technology USA

Abstract

Recent research has highlighted the ability to integrate fragmented knowledge across boundaries within a firm as a potentially potent source of competitive advantage. Yet this research raises a potent tally puzzling question: if these capabilities are so central to competitive advantage, why do they not instantaneously diffuse across an industry? This paper draws on a detailed field study of the development of hypertensive drugs in 10 major European and American firms to explore this issue. I suggest that any particular integrative competence rests on a complex set of interlinked factors that usually evolve only slowly over time. Those firms that were fortunate enough to have focused early on more 'rational' modes of drug discovery have been much more successsful in developing the integrative capabilities fundamental to modern drug discovery than those that initially achieved great success with the more traditional 'random' method of drug discovery. The results thus speak directly to evolutionary theories of competence development. They also raise intriguing questions about the relationship between the development of competence and the larger institutional context of the industry, since - both the wealth and prominence of public sector biomedical research and the use of mechanism of action as an integrative device appear to have shaped the formation of capability in the industry.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ind Corp ChangeHome page
D. G. Hoopes and T. L. Madsen
A capability-based view of competitive heterogeneity
Ind. Corp. Change, June 1, 2008; 17(3): 393 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Ind Corp ChangeHome page
L. Nesta and P.-P. Saviotti
Firm knowledge and market value in biotechnology
Ind. Corp. Change, August 1, 2006; 15(4): 625 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Science Technology SocietyHome page
G. Dutrenit
Building Technological Capabilities in Latecomer Firms: A Review Essay
Science Technology and Society, September 1, 2004; 9(2): 209 - 241.
[Abstract] [PDF]

Home page
 Organization StudiesHome page
R. Whitley
The Institutional Structuring of Innovation Strategies: Business Systems, Firm Types and Patterns of Technical Change in Different Market Economies
Organization Studies, September 1, 2000; 21(5): 855 - 886.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.